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Abstract: 
Late-life major depression (LLMD) is a risk factor for the development of mild cognitive 
impairment and dementia, including Alzheimer’s disease (AD) and vascular dementia. Immune 
dysregulation and changes in innate immune responses in particular, have been implicated in the 
pathophysiology of both LLMD and AD. Complement system, a key component of the innate 
immune mechanism, is known to play an important role in synaptic plasticity and cognitive 
functions. However, its role in LLMD remains unknown. In the present study, we examined the 
levels of complement component 3 (C3, the convergence point of all complement 
activation pathways) in the cerebrospinal fluid (CSF) of elderly depressed subjects compared to 
healthy controls; as well as the relationship of CSF C3 levels with amyloid-beta (Aβ42 and Aβ40), 
total tau (T-tau) and phosphorylated tau (P-tau) proteins and cognition scores. CSF was obtained 
from 50 cognitively intact volunteers (major depression group, N=30; comparison group, N=20) 
and analyzed for levels of C3 by ELISA. C3 levels were marginally lower in the major depression 
group relative to the comparison group. We did not find any significant association of C3 with 
the AD biomarkers Aβ42 reflecting plaque pathology, P-tau related to tau pathology or the 
neurodegeneration biomarker T-tau. In contrast, C3 was positively correlated with CSF Aβ40, 
which may reflect Aβ deposition in cerebral vessel walls. We observed a negative correlation 
between C3 levels and Total Recall on the Buschke Selective Reminding Test (BSRT) for memory 
performance in the depressed subjects when controlling for education. This initial evidence on C3 
status in LLMD subjects may have implications for our understanding of the pathophysiology of 
major depression especially in late life. 
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Introduction 
Recent evidence implicates immune dysregulation in the pathophysiology of major depressive 
disorder (MDD) (Capuron &Dantzer, 2003; Dantzer et al., 2008). Although clinical significance 
has not yet been established, a subset of depressed patients show changes in inflammatory markers 
and activation of immune cells such as resident brain microglia. Levels of pro-inflammatory 
cytokines such as interleukin-1β (IL-1β), interleukin-6 (Il-6), interleukin-8 (IL-8), and tumor 
necrosis factor (TNF-α) were found to be increased in the peripheral as well as central nervous 
systems (CNS) of a subset of depressed subjects (reviewed by Miller et al., 2006; Raison et al, 
2006). The exact mechanism by which these changes relate to depressive phenotypes is currently 
unclear; in some cases, peripheral pro-inflammatory cytokines have been found to infiltrate into 
the brain and influence brain function, leading to depressive-like behavior (Raison et al., 2006). 
Once in the CNS, they are thought to activate microglia, which then overproduce glutamate to the 
point of glutamate neurotoxicity (McNally et al., 2008). Some evidence for this hypothesis comes 
from positron emission tomography (PET) studies using ligands of translocator protein (TSPO) 
that found greater microglial activation in the prefrontal cortex (PFC) and anterior cingulate cortex 
(ACC) of patients with MDD (Setiawan et al., 2015; 2018). However, it should be noted that none 
of the current TSPO ligands are specific tracers of M1 (associated with the release of pro-
inflammatory cytokines) or M2 (accompanied by the production of anti-inflammatory molecules) 
microglia.  
Although a number of therapeutic approaches, such as antidepressant medications and 
electro-convulsive therapy (ECT), have shown to inhibit inflammatory activity with improvements 
in depressive symptoms, patients with baseline high inflammatory activity have been reported to 
be less responsive to the above approaches (Allison et al., 2019; Benedetti et al., 2002; Lanquillon 
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et al., 2000; Levine et al., 2009; Mikova et al., 2001; Słuzewska et al., 1995, 2001; Tuglu et al., 
2003).  Therefore, there is a critical need for studies that elucidate the role of the immune system 
in MDD in order to identify novel therapeutic targets.  
The complement system represents one of the major branches of the innate immune system 
and consists of cascades of proteins that ultimately activate effector molecules. The cascade can 
be initiated by three major pathways: the classical pathway, the lectin pathway, and the alternate 
pathway; all three pathways converge on the cleavage of the major complement component, C3, 
into its activated subunits. The classical pathway begins when the recognition molecule C1q binds 
to antigens or antibodies. C1q then activates the associated serine proteases C1r and C1s, leading 
to cleavage of C2 and C4, which generates the C3 convertase C3b2b. C3b2b in turn cleaves C3 
and activates downstream cascade components (Stevens et al., 2007). Working in parallel to the 
classical pathway, the lectin pathway is initiated by the molecule mannose-binding lectin (MBL) 
that recognizes mannose residues. This activates the MBL-associated proteases MBL serine 
protease 1 (MASP1) and MASP2, which cleave C4 to generate the C4 convertase, C4b2b. The 
alternative pathway meanwhile functions primarily as an amplification loop of C3b. Ultimately, 
all pathways cleave C3 into activated components C3a and C3b. C3a regulates inflammatory 
signaling via its seven-transmembrane domain receptor, C3aR (Asgari et al., 2013; Crider et al., 
2018).   
The complement system plays an important role in synaptic plasticity, and abnormalities 
in the system may contribute to the development of neurodegenerative diseases such as 
Alzheimer’s disease (AD) (Emmerling et al., 2000; Johansson et al., 2018; Morgan, 2018). 
Microglia, the innate immune cells that maintain homeostasis in the CNS, use the classical 
complement pathway to regulate synapse development (Fourgeaud and Boulanger, 2007; Stevens 
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et al., 2007), likely through the promotion of synaptic pruning. Aβ plaques have been shown to 
activate the complement system, which in turn uses activation factors such as C3a and C5a to 
trigger the activation of phagocytes, including microglia. However, findings on the role of 
complement system in neurodegeneration have reported conflicting results: some studies indicate 
that complement proteins promote neurodegeneration whereas others indicate that they provide 
neuroprotective effects (Fonseca et al., 2004; Maier et al., 2008, Wu et al., 2019; Wyss-Coray et 
al., 2002). 
A few studies have previously examined the role of complement proteins in the 
pathophysiology of depression, but the data remains in need of further investigation. Higher basal 
plasma levels of C3 (and its breakdown products) and C4 were found in depressed patients 
compared with healthy subjects in a couple of studies (Kronfol and House, 1989; Song et al., 
1994), while another study found elevated C4 but no significant difference in C3 levels in serum 
samples of depressed subjects (Berk et al., 1997). More recently, our group found a significant 
increase in C3 expression in the PFCs of depressed suicide subjects (Crider et al., 2018).  
The complement system may potentially link depression and the development of dementia 
and neurodegenerative disease in the elderly. A number of studies suggest that late-life major 
depression (LLMD) is a risk factor for the development of mild cognitive impairment and 
dementia, including AD, and vascular dementia (Diniz et al., 2013; Ownby et al., 2006; Barnes et 
al., 2012). Although the complement system has been implicated in AD and associated with 
changes in cognitive function, its role in late-life depression remains unknown. In the present 
study, we examined whether complement system links late-life depression and deterioration of 
cognitive function. We investigated the levels of C3 in the cerebrospinal fluid (CSF) of elderly 
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depressed subjects compared to healthy controls; as well as the relationship of CSF C3 levels with 
AD-relevant CSF biomarkers and cognition scores.  
 
Materials and Methods 
Participants 
This study was approved by the institutional review boards of the Nathan Kline Institute for 
Psychiatric Research and the New York University School of Medicine. All methods were 
performed in accordance with the guidelines and regulation of the National Institutes of Health, 
USA. Participants were volunteers who responded to advertisements in local newspapers and 
flyers or were recruited from the Memory Education and Research Initiative Program (Pomara 
et al., 2012). All participants provided informed consent prior to examination and received up 
to $450.00 in compensation. A total of 133 participants completed the baseline evaluation, and 
51 of these took part in the optional lumbar puncture procedure. Of these 51participants, one 
individual was excluded because of lack of C3 data. Of the 50 remaining participants, 30 were 
diagnosed with MDD by a board-certified psychiatrist, leaving 20 comparison subjects. The 
structural interview for DSM-IV disorders (SCID) was administered by a psychiatrist to 
establish an MDD diagnosis. Of the 30 patients with MDD, 21 (70%) had recurrent episodes. 
Table 1 summarizes the demographic and clinical characteristics of the study participants at 
baseline. 
 
Procedure 
The study was conducted over four visits, usually one week apart. The first three visits were 
conducted at the Nathan Kline Institute for Psychiatric Research and the Clinical and 
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Translational Science Institute, New York University Langone Medical Center. During the first 
visit, for the purpose of obtaining informed consent, the study procedures were explained and 
participants were informed of their rights. Participants’ medical and psychiatric histories, 
including any family history of AD, were also obtained, and their vital signs were measured. 
Participants then underwent a psychiatric evaluation, and their global cognitive status was 
assessed using the MMSE. Additionally, the Hamilton Depression Rating Scale (HAM-D) was 
administered to rate the severity of current depressive symptoms. Subjects who met the criteria 
for past MDD but were not currently depressed (i.e., HAM-D score below 16) were included as 
MDD subjects. Subjects underwent a comprehensive neuropsychological assessment, including 
the Buschke Selective Reminding Test (Buschke,1974), the Trail-Making Test, parts A and B 
(Army Individual Test Battery, 1994), and the category fluency test (Goodglass, and Kaplan, 
1972) during the third visit.  
 
CSF collection: A lumbar puncture was performed during the fourth visit by a neuroradiologist 
under guided fluoroscopy in a subset of participants. Prior to the procedure, which was 
performed between 9:00 a.m. and 10:00 a.m., participants were asked to fast overnight. A total 
of 15 ml of clear CSF was collected in three polypropylene tubes labeled “A” (first 5 ml), “B” 
(second 5 ml), and “C” (third 5 ml). The tubes were immediately placed on ice for a maximum 
of 1 hour until the samples were centrifuged at 4 °C (at 1500 rpm) for 10 minutes. Then, aliquots 
of 0.25 ml were placed into 1.00-ml polypropylene cryogenic vials and put into Nunc eight-cell 
storage boxes (Nalge Nunc International, Rochester, N.Y.) at −80 °C. All amyloid -β, tau, and 
C3 determinations were performed from tube “C”. 
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Amyloid Beta and Tau Protein Determination: CSF levels of amyloid beta (A40 and A42) 
were analyzed with electrochemiluminescence technology using the MS6000 Human Ab Ultra-
Sensitive Kit (Meso Scale Discovery, Gaithersburg, Md.). Total tau concentration in CSF was 
determined using a sandwich enzyme-linked immunosorbent assay (ELISA) (INNOTEST hTAU-
Ag, Fujirebio, Ghent, Belgium) specifically constructed to measure all tau isoforms, irrespective 
of phosphorylation status. Tau protein phosphorylated at threonine 181 was measured using a 
sandwich ELISA method (INNOTEST Phospho-Tau [181P], Fujirebio). 
 
C3 ELISA: Complement C3 was quantified by a Complement C3 Human ELISA kit (cat 
#ab108823; abcam, Cambridge, MA, USA). Briefly, 96-well plates were incubated with C3 
standard or sample for two hours at RT. After washing, wells were subsequently incubated with 
biotinylated C3 antibody for 1 hr at RT. Following washing, peroxidase-labelled streptavidin 
conjugate was added to each well and incubated for 30 min. After washing, chromogen substrate 
was added and incubated for 10 min. After the reaction had been stopped with a stop solution, the 
amount of reacted substrate was measured at OD 450 nm. A standard curve was made using serial 
dilutions of the standard. The amount of C3 in samples was determined from the standard curve. 
Values were expressed as ng/mL. 
 
Statistical analysis 
All statistical analyses were carried out using the IBM SPSS statistical software package, version 
24.0 for Windows (IBM Corp., Armonk, New York, USA). Distributions of data for demographic 
variables and variables of interest were evaluated using z-tests for skewness and kurtosis and were 
judged to be non-normal when a z value corresponded to alpha level .01. In those cases, 
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nonparametric tests were used, as indicated in the Results section.  A two-way (2 X 2) ANOVA 
was conducted to examine the effects of MDD status and sex on CSF C3 levels. Distributions of 
CSF C3 levels were non-normal across depression and sex subgroups and a square root 
transformation proved to be the best transformation method. Spearman correlations were used to 
test associations between untransformed C3 and AD biomarker variables (Aβ and tau). Partial 
(Pearson) correlations were used to test associations between transformed C3 values and cognitive 
scores to control for variation in years of education.  
 
Results 
Table 1 shows the demographic details of study subjects. For depression subgroups, there are 
no significant deviations from normality for age distribution, though it was positively skewed. 
For sex subgroups, the distribution of age deviated significantly from normality. Using z-tests 
for skew and kurtosis, education distributions did not deviate from normality in either 
depression of sex subgroups (N=50). Neither mean age nor education differed by MDD status: 
Age: t(48) = 0.77, p = 0.45; Education t(48) = 0.35, p = 0.73. In addition, sex groups did not 
differ by age on Mann-Whitney U test: U = 216, p = .072. LLMD subjects showed significant 
differences in the depression/anxiety scores in 17-item Ham-D and 21-item Ham-D. Cognitive 
scores measured for MMSE (Mini-Mental State Examination memory), Buschke Selective 
Reminding Test (Total and Delayed Recall) showed no significant group differences between 
controls and LLMD subjects.  
 
Effect of depression status on CSF C3 levels: We observed marginally lower mean CSF C3 levels 
in LLMD than controls (LLMD, 87.19±25.07 (N=30) vs Control, 102.51±34.93 (N=20); 
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t(48)=1.81, p=.077). Within the LLMD group, mean CSF C3 levels in subjects taking 
antidepressant medications (81.71±27.41 (N=16)) were not statistically different from mean C3 
levels in subjects not taking antidepressants (93.45±21.34 (N=14); t(28)=1.295, p=.206)).  We 
found a significant sex effect on CSF C3 levels (Male, 102.31±24.84 (N=28) vs Female, 
81.87±32.58 (N=22); t(48) = 2.514, p = 0.015). We found a significant association between CSF 
C3 and education in LLMD group (r= 0.395, p = .031, N=30). Further, 2 X 2 GLM to test for 
the interaction of LLMD and sex while controlling for education (i.e., factorial ANOVA) 
showed no interaction, but main effects of both MDD (p=0.011) and sex (p=0.008) on C3 levels 
(Table 2).  
 
Correlation of CSF C3 with amyloid-beta (Aβ40) levels in LLMD subjects. We found a 
significant positive association between C3 and Aβ40 in CSF samples of LLMD subjects 
(r=0.411; p=0.024), but not in control subjects (r=0.259; p=0.271). We did not find any 
significant association between CSF levels of C3 and Aβ42 in controls (r=0.229; p=0.332) and 
LLMD subjects (r=0.303; p=0.104). Similarly, we did not find any significant association 
between CSF levels of C3 and Aβ42/40 in controls (r=0.123; p=0.605) and LLMD subjects 
(r=0.243; p=0.195). Furthermore, no significant correlations were observed between C3 and tau 
(controls, r=-0.114; p=0.631, LLMD, r=0.162; p=0.393) or phosphoTau levels (controls, r=-
0.117; p=0.624, LLMD, r=0.176; p=0.352). 
 
Correlations between CSF C3 levels and depression scores or cognitive domain scores. Among 
the different possible correlations between CSF C3 and depression scores or cognitive domain 
scores analyzed, we observed a negative correlation between C3 levels and Total Recall on the 
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Buschke in the Depressed subjects when controlling for education (r=-0.380, p=0.046). Although 
mean HAM-D scores were significantly lower in those taking antidepressants (21.4 vs 13.8; 
p=.03), CSF C3 levels did not significantly correlate with HAM-D scores with (r=-.153, p=.421) 
or without (r=.047, p=.806) controlling for medication status. 
 
 
Discussion 
In CSF samples of LLMD subjects, C3 levels were marginally reduced compared to 
healthy controls; and lower C3 levels correlated with lower Aβ40 levels. We observed a negative 
correlation between C3 levels and Total Recall on the BSRT in the depressed subjects. These 
findings provide the first evidence of altered C3 levels in CSF of depressed subjects as compared 
to healthy controls, as well as evidence that it may be associated with cognitive impairment. 
There exist two possible sources of complement in the brain: those produced in the 
periphery that enter the CNS, or those produced in the CNS itself. Unlike cytokines, which can 
enter the brain through transporters on the brain endothelium, peripherally-derived complement 
components can only enter the brain through a compromised blood-brain barrier (Veerhius et al., 
2011). Centrally-derived complement components are likely produced by glial cells such as 
microglia and astrocytes which have been shown to synthesize most components of at least the 
classical and alternative pathways, leading to a functional complement system in the CNS 
modulated by pro-inflammatory cytokines such as IL-1Β and TNF-alpha (Gasque et al., 1995; 
Veerhuis et al., 1999; Walker et al., 1995). In addition, neurons themselves are also able to produce 
both classical and alternative pathway components (Rus et al., 2006). These studies suggest that 
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CNS is capable of producing complement proteins independent of peripheral complement system, 
if needed.  
While the studies directly linking depression and complement in the CNS are limited, given 
the known effects of complement, it was hypothesized that complement is abnormally activated or 
upregulated in depressed patients. However, we observed a reduction in CSF C3 levels in LLMD 
subjects. The decrease in C3 levels may reflect a decrease in C3 production in LLMD subjects 
relative to non-depressed controls. It is also possible that the reduction in C3 is a result of increased 
cleavage of C3 into C3a and C3b, and thus actually reflecting increased downstream complement 
signaling mediated by proteins such as C5. Further analyses of C3a and C3b levels are necessary 
to determine the underlying mechanism for the observed reduction in C3 in LLMD subjects.  
C3 levels were positively correlated with Aβ40 in CSF samples of LLMD subjects; 
lower C3 levels reflected lower Aβ40 levels, a finding in line with previous studies. An earlier 
study from our group has reported decreases in Aβ42 and Aβ40 in CSF samples of LLMD 
subjects (Pomara et al., 2012), possibly due to increased deposition in formation of brain amyloid 
beta plaques in the case of Aβ42 or decreased soluble amyloid beta production. A reduction in 
CSF Aβ40, is also consistent with its preferential deposition in cerebral blood vessels as in cerebral 
amyloid angiopathy (Matsuo et al., 2018; Zabel et al., 2012).  The latter has also been linked to 
distal complement activation (Matsuo et al., 2018) and taken together, they would be consistent 
with the reductions in both CSF C3 and Aβ40 that we observed and their positive correlation.  
These results if confirmed might provide a possible mechanism for the increased cerebrovascular 
pathology which has been reported in depression especially LLMD (Aizenstein et al., 2016; Taylor 
et al., 2013).  As previously stated, further data are needed to clarify the relationship between 
complement activity and the development of AD. C1q deficiency in the Tg2576 mouse model of 
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AD resulted in reduction in microgliosis and rescue of neuronal integrity as compared to Tg2576 
mice (Fonseca et al., 2004), indicating that complement activity may  promote neuronal 
degeneration. In a recent study using mouse models of amyloidosis (PS2APP) and more 
extensively tauopathy (TauP301S), Wu et al., 2019 showed that C3 is increased in glial cells in 
the above mice and deleting C3 rescues plaque-associated synapse loss in PS2APP mice and 
ameliorates neuron loss and brain atrophy in TauP301S mice. Further, they found increased levels 
of C3 protein in brain and CSF samples of AD patients and C3 levels were correlated with tau (Wu 
et al., 2019). Contradictory to the above studies, a few complement proteins have been shown to 
provide protective effects such as decreasing neuropathology in rodent models of AD (Maier et 
al., 2008; Wyss-Coray et al., 2002) or limiting neurodegeneration in injury models (Pasinetti et al., 
1996; Pisalyaput &Tenner, 2008; Rahpeymai et al., 2006). Together, these studies suggest that 
although C3 can be protective in the clearance of Aβ deposits, it could accelerate neuronal 
dysfunction in response to tau pathology.  
Although our findings provide the initial evidence on the status of C3 in the CSF of 
LLMD subjects, our study has a number of limitations. First, most of the LLMD subjects in our 
study were medicated and the observed decrease in C3 levels could be a result of medication 
effects. Second, most of the studies conducted to date have examined inflammatory status in 
early stage depressed subjects. The LLMD subjects in our study were chronically depressed and 
may have inflammatory profiles different from patients with less sustained symptoms. It is 
possible that CSF levels of pro-inflammatory as well as anti-inflammatory markers change over 
time or with age in depressed subjects. Finally, our study was conducted in a relatively small 
number of subjects and therefore, additional studies with a larger cohort of samples are 
warranted. 
14 
 
In future studies, it will be important to determine whether changes in CSF C3 levels 
correlate with microglial activation in depressed subjects, as we may be able to identify a 
physiological mechanism behind the observed reduction in CSF C3 levels in LLMD subjects in 
our study. Also, there might be subtypes of MDD, with microglial decline and suppression (rather 
than microglial activation), which could occur due to aging or chronic stress conditions (Yirmia et 
al., 2015). Microglial activation, as determined by TSPO VT, was found greater in patients with 
chronologically advanced major depressive disorder with long periods of no antidepressant 
treatment than in patients with major depressive disorder with short periods of no antidepressant 
treatment, suggesting a differential microglial activation status between these illness stages 
(Setiawan et al., 2018).  However, the TPSO-based PET has limitations due to the lack of 
specificity for M1 vs M2 microglial phenotype. Recently, some subtypes of purinergic receptors 
such as P2X7R and P2Y12R, have been validated as promising PET imaging targets for microglia 
phenotypes in preclinical studies. These tracers will be important for microglial activation studies 
in depression, given that microglial phenotypes vary according to disease stage.  
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Tables: 
Table 1. Demographic and Memory Characteristics of Study Participants by MDD diagnosis; 
Data are the mean ± standard deviation. 
  
Characteristic Comparison Group MDD Group   
  (N=20) (N=30) p values (t tests) 
Age (years) 68.4 ± 7.2 66.9 ± 5.3 0.39 
Education (years) 16.6 ± 2.6 16.4 ± 2.7 0.7 
21-item HAM-D 1.2 ± 1.9 14.9 ± 8.8 <0.001 
17-item HAM-D 1.2 ± 1.8 15.5 ± 8.7 <0.001 
MMSE 29.5 ± 0.5 29.7 ± 0.8 0.47 
Total recall rating 64.5 ± 12.0 62.8 ± 14.9 0.68 
Delayed recall rating 8.4 ± 2.7 9.2 ± 2.7 
0.33 
 
      p values (χ2) 
Females (n) 12 (60%) 10 (35%) 0.15 
21-item HAM-D: 21-item Hamilton Depression Rating Scale, MMSE: Mini-Mental State 
Examination. 
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Table 2. Effect of both Depression status and sex on CSF C3 levels.  
 
 
 
Source Type III Sum 
of Squares 
df Mean 
Square 
F Sig. Partial Eta 
Squared Corrected Model 11553.290a 4 2888.323 3.978 0.008 0.261 
Intercept 5739.346 1 5739.346 7.904 0.007 0.149 
LLMD 5087.734 1 5087.734 7.007 0.011 0.135 
sex 5506.151 1 5506.151 7.583 0.008 0.144 
LLMD * sex 312.977 1 312.977 0.431 0.515 0.009 
Edu 535.725 1 535.725 0.738 0.395 0.016 
Error 32675.116 45 726.114 
   
Total 479652.577 50 
    
Corrected Total 44228.406 49 
    
a. R Squared = .261 (Adjusted R Squared = .196) 
